Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Website: catalystpharma.com



Growth: Good revenue growth rate 14.7%, there is slowdown compared to average historical growth rates 49.0%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +44.6%. On average the margin is improving unsteadily. Gross margin is high, +82.9%. In the last quarter the company beat the estimated EPS, +28.1%. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 8.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 108.6% higher than minimum and 8.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 5.7x by EV / Sales multiple , the company can be 45.6% undervalued

Insiders: For the last 3 months insiders bought company shares on $0.3 mln (0.011% of cap.)

Key Financials (Download financials)

Ticker: CPRX
Share price, USD:  (0.0%)23.99
year average price 22.34  


year start price 22.56 2025-02-01

max close price 26.31 2025-06-10

min close price 19.13 2025-09-25

current price 23.99 2026-01-31
Common stocks: 122 600 730

Dividend Yield:  0.0%
FCF Yield LTM: 8.4%
EV / LTM EBITDA: 8.7x
EV / EBITDA annualized: 8.5x
Last revenue growth (y/y):  +14.7%
Last growth of EBITDA (y/y):  +29.4%
Historical revenue growth:  +49.0%
Historical growth of EBITDA:  +46.1%
EV / Sales: 3.9x
Margin (EBITDA LTM / Revenue): 44.6%
Fundamental value created in LTM:
Market Cap ($m): 2 941
Net Debt ($m): -687
EV (Enterprise Value): 2 254
Price to Book: 3.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-28zacks.com

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

2026-01-24fool.com

2 Under-the-Radar Biotech Stocks Set to Boom in 2026

2026-01-12seekingalpha.com

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-30zacks.com

Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term

2025-12-23zacks.com

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock

2025-12-17zacks.com

CPRX vs. DSNKY: Which Stock Is the Better Value Option?

2025-12-05zacks.com

Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue?

2025-12-02seekingalpha.com

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

2025-12-02zacks.com

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

2025-12-01zacks.com

CPRX or DSNKY: Which Is the Better Value Stock Right Now?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-08-07 2024-05-08 2023-11-08 2023-08-09 2023-05-10 2022-11-09
acceptedDate 2025-11-05 16:02:31 2025-08-06 16:08:25 2025-02-26 16:05:35 2024-11-06 16:08:22 2024-08-07 16:05:35 2024-05-08 16:06:47 2024-02-28 17:16:26 2023-11-08 16:06:08 2023-08-09 16:07:07 2023-05-10 16:07:06 2023-04-24 16:30:59 2022-11-09 16:07:39 2022-04-29 16:32:31 2021-03-15 17:17:20
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 148M 147M 492M 129M 123M 99M 398M 103M 100M 85M 214M 57M 141M 119M
costOfRevenue 25M 30M 69M 19M 25M 13M 52M 14M 12M 10M 34M 10M 22M 17M
grossProfit 123M 117M 423M 109M 98M 86M 346M 89M 88M 75M 180M 48M 119M 102M
grossProfitRatio 0.829 0.796 0.85 0.798 0.873 0.862 0.879 0.883 0.831
researchAndDevelopmentExpenses 3M 4M 13M 3M 3M 3M 93M 84M 4M 4M 20M 8M 17M 16M
generalAndAdministrativeExpenses 45M 42M 168M 17M 14M 22M 47M 12M 10M 12M 54M 7M 23M 21M
sellingAndMarketingExpenses 3M 4M 10M 29M 26M 25M 87M 22M 18M 18M 3M 8M 26M 24M
sellingGeneralAndAdministrativeExpenses 47M 46M 178M 46M 41M 47M 134M 34M 28M 30M 57M 14M 50M 44M
otherExpenses 7M 0 37M 9M 9M 2M 33M -833 000 2M 7M 1M 0 0 0
operatingExpenses 57M 50M 228M 59M 44M 59M 259M 126M 41M 40M 78M 22M 67M 61M
costAndExpenses 82M 80M 297M 78M 68M 71M 311M 140M 53M 50M 112M 32M 88M 78M
interestIncome 0 6M 16M 0 0 0 0 0 2M 0 0 0 0 0
interestExpense 0 0 0 0 0 0 0 0 0 -2M 0 -905 000 0 0
depreciationAndAmortization 9M 9M 38M 0 10M 9M 33M 9M 9M 7M 1M 553 000 192 000 92 000
ebitda 80M 79M 233M 51M 54M 37M 120M -29M 55M 42M 103M 26M 53M 41M
ebitdaratio 0.542 0.537 0.396 0.52 0.371 -0.279 0.555 0.494 0.448
operatingIncome 66M 66M 195M 51M 54M 27M 87M -37M 47M 36M 102M 25M 52M 41M
operatingIncomeRatio 0.447 0.452 0.396 0.442 0.275 -0.362 0.469 0.417 0.439
totalOtherIncomeExpensesNet 5M 3M 21M 6M 2M 2M 8M -833 000 2M 2M 3M 905 000 282 000 587 000
incomeBeforeTax 71M 69M 216M 57M 56M 29M 95M -38M 49M 37M 105M 26M 53M 42M
incomeBeforeTaxRatio 0.479 0.473 0.445 0.455 0.295 -0.37 0.487 0.437 0.454
incomeTaxExpense 18M 17M 52M 13M 15M 6M 23M -7M 11M 8M 22M 3M 13M -33M
netIncome 53M 52M 164M 44M 41M 23M 71M -31M 38M 30M 83M 23M 39M 75M
netIncomeRatio 0.356 0.356 0.341 0.332 0.236 -0.3 0.379 0.346 0.397
eps 0.43 0.43 1.38 0.37 0.35 0.2 0.67 -0.29 0.36 0.28 0.8 0.22 0.38 0.72
epsdiluted 0.42 0.41 0.35 0.33 0.19 -0.29 0.33 0.26 0.2
weightedAverageShsOut 123M 122M 118M 119M 118M 117M 106M 107M 114M 106M 103M 103M 103M 104M
weightedAverageShsOutDil 127M 128M 125M 125M 125M 123M 114M 107M 114M 114M 111M 112M 108M 106M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-28 2023-04-24 2022-04-29 2021-03-15
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 16M 0 0 0 0
ebit 195M 87M 102M 52M 41M
nonOperatingIncomeExcludingInterest 0 0 0 0 0
netIncomeFromContinuingOperations 164M 71M 83M 39M 75M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 164M 71M 83M 39M 75M
epsDiluted 1.31 0.63 0.75 0.37 0.71

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-08-07 2024-05-08 2023-11-08 2023-08-09 2023-05-10 2022-11-09
acceptedDate 2025-11-05 16:02:31 2025-08-06 16:08:25 2025-02-26 16:05:35 2024-11-06 16:08:22 2024-08-07 16:05:35 2024-05-08 16:06:47 2024-02-28 17:16:26 2023-11-08 16:06:08 2023-08-09 16:07:07 2023-05-10 16:07:06 2023-04-24 16:30:59 2022-11-09 16:07:39 2022-04-29 16:32:31 2021-03-15 17:17:20
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 690M 653M 518M 442M 376M 310M 138M 121M 179M 148M 298M 256M 171M 130M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 20M 10M
cashAndShortTermInvestments 690M 653M 518M 442M 376M 310M 138M 121M 179M 148M 298M 256M 191M 140M
netReceivables 107M 66M 65M 58M 57M 60M 54M 48M 43M 33M 11M 10M 7M 6M
inventory 28M 19M 20M 20M 18M 20M 16M 9M 11M 10M 7M 7M 8M 5M
otherCurrentAssets 28M 21M 1M 18M 24M 143 000 489 000 352 000 361 000 7M 0 466 000 327 000 883 000
totalCurrentAssets 852M 759M 624M 539M 474M 405M 219M 192M 241M 199M 321M 276M 210M 159M
propertyPlantEquipmentNet 3M 3M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 130 000
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 129M 138M 157M 166M 175M 185M 194M 167M 176M 184M 32M 33M 0 0
goodwillAndIntangibleAssets 129M 138M 157M 166M 175M 185M 194M 167M 176M 184M 32M 33M 0 0
longTermInvestments 19M 21M 22M 15M 13M 15M 16M 13M 179M 0 0 0 0 0
taxAssets 48M 51M 46M 48M 40M 38M 37M 37M 23M 20M 19M 20M 24M 33M
otherNonCurrentAssets 0 0 0 0 0 0 0 0 -179M 0 0 9000 9000 9000
totalNonCurrentAssets 199M 213M 228M 233M 232M 242M 251M 221M 203M 208M 55M 57M 28M 33M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 052M 972M 851M 772M 706M 647M 470M 413M 444M 407M 376M 333M 238M 192M
accountPayables 9M 6M 17M 12M 7M 10M 15M 5M 4M 3M 4M 3M 3M 4M
shortTermDebt 428 000 419 000 0 393 000 385 000 377 000 0 361 000 353 000 345 000 0 330 000 0 0
taxPayables 0 439 000 894 000 0 15 000 7M 729 000 912 000 5M 18M 9M 4M 79 000 0
deferredRevenue 0 0 0 0 15 000 68M 0 52M 47M 0 0 0 0 0
otherCurrentLiabilities 119M 107M 11M 93M 85M 631 000 51M 374 000 455 000 53M 5M 42M 4M 4M
totalCurrentLiabilities 129M 113M 121M 105M 92M 80M 76M 58M 53M 57M 58M 45M 27M 23M
longTermDebt 2M 3M 0 3M 6M 3M 0 3M 3M 3M 0 4M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 161 000 309 000 315 000 3M -595 000 3M 3M 4M 13M 13M 14M 16M 0 0
totalNonCurrentLiabilities 3M 3M 3M 6M 5M 6M 6M 7M 16M 17M 18M 18M 4M 0
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 3M 3M 3M 393 000 3M 3M 4M 4M 4M 3M 4M 4M 4M 29 000
totalLiabilities 131M 116M 124M 111M 98M 85M 82M 65M 69M 74M 75M 63M 31M 23M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 123 000 122 000 121 000 119 000 119 000 118 000 107 000 107 000 107 000 106 000 105 000 104 000 103 000 104 000
retainedEarnings 447M 394M 285M 229M 185M 145M 121M 86M 117M 79M 50M 24M -26M -54M
accumulatedOtherComprehensiveIncomeLoss 0 31 000 64 000 0 -0 -0 14 000 15 000 19 000 11 000 24 000 32 000 -148 000 31 000
othertotalStockholdersEquity 473M 462M 432M 423M 417M 262M 258M 254M 246M
totalStockholdersEquity 920M 856M 728M 661M 609M 561M 388M 349M 375M 334M 300M 270M 207M 170M
totalEquity 920M 856M 728M 661M 609M 561M 388M 349M 375M 334M 300M 270M 207M 170M
totalLiabilitiesAndStockholdersEquity 1 052M 972M 772M 706M 647M 413M 444M 407M 333M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 052M 972M 851M 772M 706M 647M 470M 413M 444M 407M 376M 333M 238M 192M
totalInvestments 19M 21M 22M 15M 13M 15M 16M 13M 179M 0 0 0 20M 10M
totalDebt 3M 3M 3M 3M 3M 3M 4M 4M 4M 3M 4M 4M 4M 29 000
netDebt -687M -650M -514M -439M -372M -307M -134M -117M -175M -145M -295M -252M -167M -130M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-28 2023-04-24 2022-04-29 2021-03-15
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 65M 54M 10M 7M 6M
otherReceivables 11 000 0 354 000 105 000 0
prepaids 20M 12M 5M 4M 7M
totalPayables 21M 16M 26M 3M 4M
otherPayables 4M 729 000 22M 79 000 0
accruedExpenses 88M 9M 26M 20M 14M
capitalLeaseObligationsCurrent 402 000 369 000 337 000 308 000 29 000
capitalLeaseObligationsNonCurrent 3M 3M 4M 4M 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 442M 266M 250M 233M 223M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX CPRX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-08-07 2024-05-08 2023-11-08 2023-08-09 2023-05-10 2022-11-09
acceptedDate 2025-11-05 16:02:31 2025-08-06 16:08:25 2025-02-26 16:05:35 2024-11-06 16:08:22 2024-08-07 16:05:35 2024-05-08 16:06:47 2024-02-28 17:16:26 2023-11-08 16:06:08 2023-08-09 16:07:07 2023-05-10 16:07:06 2023-04-24 16:30:59 2022-11-09 16:07:39 2022-04-29 16:32:31 2021-03-15 17:17:20
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 53M 52M 164M 44M 41M 23M 71M -31M 38M 30M 83M 23M 39M 75M
depreciationAndAmortization 9M 9M 38M 9M 10M 9M 33M 9M 9M 7M 1M 553 000 192 000 885 317
deferredIncomeTax 2M -2M -9M -9M -2M -2M -18M -14M -3M -2M 5M 934 000 9M -33M
stockBasedCompensation 6M 8M 22M 4M 4M 8M 14M 4M 3M 3M 8M 2M 6M 0
changeInWorkingCapital -40M 946 000 31M 26M 9M -9M -37M -4M -16M -26M 14M 11M 5M -4M
accountsReceivables -41M 5M -12M -1M 3M -7M -43M -5M -9M -23M -4M 250 000 -632 000 5M
inventory -9M 455 000 -4M -2M 2M -4M -5M 2M -423 000 577 000 1M 718 000 -3M -3M
accountsPayables 4M -6M 2M 4M -3M -5M 11M 177 000 1M -584 000 1M 214 000 -1M 138 573
otherWorkingCapital 6M 758 000 45M 25M 7M 7M -330 000 -251 000 -7M 23M 15M 10M 10M -6M
otherNonCashItems 2M 4M -6M -3M 24M 153 000 80M 81M 65 000 194 000 5M 4M 287 000 6M
netCashProvidedByOperatingActivities 32M 71M 240M 73M 64M 32M 144M 45M 31M 12M 116M 41M 60M 45M
investmentsInPropertyPlantAndEquipment 0 -26 000 -556 000 -259 000 -10000 -199 000 -231 000 -79M 0 -74 000 -29 000 -29 000 -1M -11 398
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 10M 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 -13M -13M 0 0 -10M 0 -10M -10M
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 19M 10M 0 5M
otherInvestingActivites 0 0 0 0 0 -79M 0 -162M -10M
netCashUsedForInvestingActivites 0 -26 000 -259 000 -10000 -199 000 -93M 0 -162M -132 000
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 2M -2M 2M 141M 212 000 617 000 1M 0
commonStockRepurchased 0 0 -296 000 296 000 0 -296 000 0 0 -52 000 0 -7M -7M -12M 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 5M -1M -6M 1M -1M -10M -779 000 -1M 11M
netCashUsedProvidedByFinancingActivities 5M 872 000 -6M 1M 141M -10M -214 000 149 000 4M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 61M 0 0 0 0 0 0
netChangeInCash 37M 72M 380M 67M 65M 173M -161M -58M 31M -150M 127M 45M 41M 41M
cashAtEndOfPeriod 690M 653M 518M 442M 376M 310M 138M 121M 179M 148M 298M 256M 171M 130M
cashAtBeginningOfPeriod 653M 581M 138M 376M 310M 138M 298M 179M 148M 298M 171M 211M 130M 90M
operatingCashFlow 32M 71M 240M 73M 64M 32M 144M 45M 31M 12M 116M 41M 60M 45M
capitalExpenditure 0 -26 000 -556 000 -259 000 -10000 -199 000 -82M -79M 0 -74 000 -29 000 -29 000 -1M -11 394
freeCashFlow 32M 71M 239M 73M 64M 32M 62M -34M 31M 12M 116M 41M 59M 45M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-28 2023-04-24 2022-04-29 2021-03-15
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 -280M -10M 0 0
netCashProvidedByInvestingActivities -556 000 -294M 9M -11M -5M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 141M 0 -7M -12M 758 130
netCommonStockIssuance 141M 0 -7M -12M 758 130
commonStockIssuance 141M 0 0 0 758 130
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -39 000 -11M 9M 4M -56 197
netCashProvidedByFinancingActivities 141M -11M 2M -8M 701 933
incomeTaxesPaid 68M 50M 8M 3M 0
interestPaid 1M 705 000 0 0 0

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-07 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-27 ET (fiscal 2024 q4)
2024 q3
2024-11-07 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-29 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-10 ET (fiscal 2023 q2)
2023 q1
2023-05-11 ET (fiscal 2023 q1)
2022 q4
2023-03-16 ET (fiscal 2022 q4)
2022 q3
2022-11-10 ET (fiscal 2022 q3)
2022 q2
2022-08-10 ET (fiscal 2022 q2)
2022 q1
2022-05-11 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-11-05 16:26 ET
Catalyst Pharmaceuticals published news for 2025 q3
SEC form 8
2025-11-05 16:26 ET
Catalyst Pharmaceuticals published news for 2025 q3
SEC form 10
2025-11-05 16:02 ET
Catalyst Pharmaceuticals reported for 2025 q3
SEC form 8
2025-08-06 20:50 ET
Catalyst Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-06 20:50 ET
Catalyst Pharmaceuticals published news for 2025 q2
SEC form 10
2025-08-06 20:08 ET
Catalyst Pharmaceuticals reported for 2025 q2
SEC form 8
2025-05-07 20:27 ET
Catalyst Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-07 20:27 ET
Catalyst Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-07 20:09 ET
Catalyst Pharmaceuticals reported for 2025 q1
SEC form 10
2025-05-07 00:00 ET
Catalyst Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-26 00:00 ET
Catalyst Pharmaceuticals reported for 2024 q4
SEC form 10
2024-11-06 16:08 ET
Catalyst Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-07 16:05 ET
Catalyst Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-07 00:00 ET
Catalyst Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Catalyst Pharmaceuticals reported for 2024 q1
SEC form 10
2024-02-28 17:16 ET
Catalyst Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Catalyst Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-08 16:06 ET
Catalyst Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Catalyst Pharmaceuticals published news for 2023 q3
SEC form 6
2023-08-09 16:34 ET
Catalyst Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-09 16:07 ET
Catalyst Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Catalyst Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-28 16:30 ET
Catalyst Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-21 16:30 ET
Catalyst Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-12 16:31 ET
Catalyst Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-23 16:31 ET
Catalyst Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Catalyst Pharmaceuticals published news for 2023 q1
SEC form 6
2023-04-10 16:30 ET
Catalyst Pharmaceuticals published news for 2023 q1
SEC form 6
2023-03-31 16:45 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 6
2023-03-15 16:41 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 10
2023-03-15 16:06 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 10
2023-03-15 00:00 ET
Catalyst Pharmaceuticals reported for 2022 q4
SEC form 6
2023-03-07 16:40 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 6
2023-02-07 08:19 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-30 16:15 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-24 16:30 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-23 08:25 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 6
2022-12-22 16:31 ET
Catalyst Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-09 16:32 ET
Catalyst Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-09 16:07 ET
Catalyst Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Catalyst Pharmaceuticals reported for 2022 q3
SEC form 6
2022-09-29 16:30 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 6
2022-09-19 17:28 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 6
2022-09-09 16:30 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 6
2022-08-09 17:11 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-09 16:09 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Catalyst Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-05 16:30 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 6
2022-07-12 08:30 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 6
2022-05-10 16:31 ET
Catalyst Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-10 16:07 ET
Catalyst Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Catalyst Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-29 16:32 ET
Catalyst Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-16 16:53 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-16 16:06 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-16 00:00 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-11 16:15 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-02 17:00 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-07 16:49 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:55 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-28 17:17 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-10 16:17 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-06 16:30 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 6
2021-12-03 17:28 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-12 16:31 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-09 17:29 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-09 16:07 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-26 16:46 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 6
2021-09-30 17:13 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-16 16:13 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-09 17:28 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-09 16:34 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-19 16:21 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-06 08:15 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-30 16:30 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-29 08:22 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-28 17:02 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-03 17:06 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-10 17:43 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-10 17:23 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-30 16:31 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-22 08:35 ET
Catalyst Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-16 08:11 ET
Catalyst Pharmaceuticals published news for 2020 q4
SEC form 10
2021-03-15 17:17 ET
Catalyst Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-06 16:28 ET
Catalyst Pharmaceuticals published news for 2020 q4
SEC form 6
2020-11-09 17:46 ET
Catalyst Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-09 17:09 ET
Catalyst Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-19 08:04 ET
Catalyst Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-06 17:26 ET
Catalyst Pharmaceuticals published news for 2020 q3
SEC form 6
2020-09-29 19:38 ET
Catalyst Pharmaceuticals published news for 2020 q2